ArticleACS omega2025
Use of Mesenchymal Stem Cell-Targeting 3WJ Nanoparticles and Reported Specific Delivery of Anti-miRNA 138 to Treat Osteoporosis.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advanced bone-targeted nanomaterials for the systemic treatment of osteoporosis.Regenerative biomaterials · 2026Review
- Nonlinear Magnetic Response Measurements in Study of Magnetic Nanoparticles Uptake by Mesenchymal Stem Cells.Nanomaterials (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLocked nucleic acid (LNA)-modified anti-microRNAs have been demonstrated to target mesenchymal stem cells (MSCs) to treat bone diseases. However, the "off-target" effect limits its clinical application.
methodsWe selected specific aptamer M4 of MSCs and employed the three-way junction (3WJ) as the core scaffold to construct nanoparticles (3WJ-M4-LNA) for specific delivery of anti-miRNA 138.
resultsOur results suggested that the 3WJ-M4-LNA nanoparticles, not 3WJ-M4 or 3WJ-LNA, can specifically deliver anti-miRNA to MSCs, resulting in significant inhibition of miRNA 138 expression. Our experiment further confirmed that the nanoparticles can promote MSCs' osteogenic differentiation by activating the ERK1/2 pathway. In vivo, the nanoparticles promoted bone formation and improved the bone microarchitecture in rabbit osteoporosis models.
conclusionsThese results indicate that the 3WJ nanoparticles could develop as a specific therapeutic strategy for osteoporosis.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.